$WT

WisdomTree, Inc. Q2 2026 Earnings Call Summary

WisdomTree, Inc. reported a sixth straight quarter of record AUM at $162.9 billion and adjusted operating margins up 900 bps to 41.1%. Management said it expects about 15 new ETFs in 18 months, continued share repurchases, and revised interest income guidance to $8 million from $10 million.

Original reporting
Published Aug 2, 2026, 4:15 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 2, 2026, 4:31 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
WisdomTree, Inc. Q2 2026 Earnings Call Summary — source image
Decision brief

The 30-second read

$WTNeutralMed
01

Why it matters

Traders can update H2 earnings expectations using the revised interest income guidance and the stated diluted share count range, while also monitoring execution risk around Atlantic House fee timing and regulatory progress for tokenized ETFs.

02

Market read

The call provides actionable forward-looking inputs (interest income guide cut, share count assumptions) and execution milestones (15 new ETFs, tokenized ETF filing) that can reprice near-term earnings and longer-term growth optionality.

03

What to watch

Atlantic House structuring fees are described as sporadic and dependent on launch timing, which can make quarterly revenue less predictable than the AUM and margin narrative suggests.

Relevance 6/10Novelty 6/10Timing: ahead of H2 execution, with guidance assumptions for diluted share count and interest income

Background

WisdomTree’s Q2 2026 earnings call emphasizes record AUM, margin expansion, and strategic expansion through the Atlantic House acquisition, alongside a tokenization platform roadmap.

Company-level read

Ticker impact

$WTNeutralMedium confidence
Context

WisdomTree guided H2 interest income to $8M from $10M and reiterated buybacks, tokenized ETF pipeline, and Atlantic House fee volatility.

Expected impact

Near-term downside risk from the reduced interest income guide, partially offset by buyback emphasis and incremental ETF/tokenization catalysts.

Evidence & confidence

The article provides specific forward-looking financial guidance (interest income) and concrete operational plans (15 new ETFs, tokenized ETF filing), which can shift expectations for H2 earnings power and capital return timing.

Market effects

Highlights ongoing regulatory uncertainty for tokenized products and potential competitive pressure in ETF launches and tokenization platforms.

Emphasizes expansion from UK into U.S. and Europe via Atlantic House, which could affect regional product mix and fee structures.

Tokenization and private-markets distribution themes remain globally relevant, but the article’s specifics are company-execution focused.

Counterpoint

The tokenization and new-ETF pipeline may be longer-dated than the market expects, so the near-term earnings guide cut could dominate price action.

Key entities

  • WisdomTree, Inc.

    Discussed Q2 2026 performance, revised H2 interest income guidance, buyback plans, and tokenized ETF pipeline.

  • Atlantic House

    Integration focus for derivatives-based and outcome-oriented solutions, with potentially volatile structuring fees.

  • Ceres (Fund I and Fund II)

    Transition from Fund I to Fund II in June, affecting flow cadence and performance fee normalization.

Related articles

$WTMed

WisdomTree (WT) Stock Is Up, What You Need To Know

WisdomTree (WT) stock rose 2.9% after Goldman Sachs increased its price target to $21.30, citing improved earnings and industry outlook. Shares later settled at $24.40, up 1.5% from the previous close. WT has seen volatility, with 11 moves over 5% in the past year. The stock is up 95% YTD, near its 52-week high of $25.04.

$WTMed

WT Maintained by Craig-Hallum -- Price Target Raised to $29.00

Craig-Hallum raised its price target for WisdomTree (WT) to $29.00 from $24.00, maintaining a 'Buy' rating. The stock is currently priced at $24.73, which GuruFocus deems 40.1% overvalued. WT has a GF Score™ of 82/100, showing strong performance but concerns over valuation. Insiders have sold $736,800 in shares recently, with no purchases.

$WTMed

WT Maintained by Goldman Sachs -- Price Target Raised to $21.30

Goldman Sachs maintained a Neutral rating on WisdomTree (WT) but raised its price target to $21.30 from $18.30. GuruFocus values WT at $17.65, suggesting a 41% overvaluation. The company has a GF Score of 82/100, with strong profitability and growth but low valuation metrics. Insiders have sold $736,800 worth of shares in the last three months.

$WTMed

Should You Buy WisdomTree (WT) Stock After Its Latest Crypto Move?

WisdomTree (WT) reported record AUM of $162.9B in Q2 2026, up 30% YoY, with revenue at $177.2M and 40.5% operating margin. The company partnered with MoonPay to integrate its tokenized fund WTGXX, accessing 35M accounts. Despite GAAP losses from debt repurchases, management highlights long-term growth potential in digital assets. WT trades at a forward P/E of 17.30.

$WTMed

WisdomTree Announces Second Quarter 2026 Results

WisdomTree, Inc. (WT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 WisdomTree Announces Second Quarter 2026 Results Record AUM of $162.9 Billion Diluted Earnings Per Share of $0.28; Adjusted Earnings Per Share of $0.31 13% Annualized Organic Flow Growth Rate Operating Margin Expanded by 780 bps Year over Year; or 900 bps, on an Adju

$WTMed

WisdomTree (NYSE:WT) Delivers Strong Q2 CY2026 Numbers

Asset management firm WisdomTree (NYSE: WT) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 57.3% year on year to $177.2 million. Its non-GAAP profit of $0.31 per share was 17.3% above analysts’ consensus estimates. Is now the time to buy WisdomTree? Find out by accessing our full research report, it’s free. "The second quarter demonstrated the quality of WisdomTree's growth.